Compare Stocks → You need to know these two things about AI stocks ASAP… (From InvestorPlace) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AVDLNASDAQ:FIXXNASDAQ:INZYNASDAQ:SIGANASDAQ:SPRB Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVDLAvadel Pharmaceuticals$15.83-2.6%$16.75$9.50▼$19.09$1.43B1.611.23 million shs2.49 million shsFIXXHomology Medicines$1.18$0.46▼$17.51$978.01M-0.1390,307 shs22,300 shsINZYInozyme Pharma$4.65+0.2%$5.59$2.69▼$7.80$287.65M1.54604,275 shs459,780 shsSIGASIGA Technologies$7.75+3.3%$8.08$4.22▼$10.83$551.18M0.95763,855 shs1.73 million shsSPRBSpruce Biosciences$0.84-1.2%$1.63$0.67▼$5.95$34.50M2.51.04 million shs721,612 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVDLAvadel Pharmaceuticals-2.58%-13.50%-5.61%+9.78%+2.13%FIXXHomology Medicines0.00%0.00%+1,700.00%+4,736.74%+3,333.24%INZYInozyme Pharma+0.22%0.00%-15.15%-20.10%-29.86%SIGASIGA Technologies+3.33%-17.90%-16.40%+58.16%+32.93%SPRBSpruce Biosciences-0.84%+13.05%+9.12%-80.64%-63.63%Tech GIANT’s Plans to Revolutionize Crypto… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVDLAvadel Pharmaceuticals2.4606 of 5 stars4.51.00.00.01.51.70.6FIXXHomology Medicines2.3274 of 5 stars3.30.00.04.80.00.80.6INZYInozyme Pharma1.5664 of 5 stars3.51.00.00.01.73.30.0SIGASIGA Technologies0.3749 of 5 stars0.02.00.00.02.50.81.3SPRBSpruce Biosciences3.4761 of 5 stars4.15.00.00.00.02.51.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVDLAvadel Pharmaceuticals3.00Buy$24.1752.66% UpsideFIXXHomology Medicines2.50Moderate Buy$0.75∞ UpsideINZYInozyme Pharma3.00Buy$17.00265.59% UpsideSIGASIGA TechnologiesN/AN/AN/AN/ASPRBSpruce Biosciences2.25Hold$5.67575.89% UpsideCurrent Analyst RatingsLatest FIXX, SPRB, AVDL, INZY, and SIGA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2024AVDLAvadel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$25.00 ➝ $27.005/9/2024AVDLAvadel PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $23.005/8/2024AVDLAvadel PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.005/8/2024INZYInozyme PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.005/7/2024INZYInozyme PharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$15.004/9/2024AVDLAvadel PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.004/9/2024INZYInozyme PharmaBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $14.004/9/2024INZYInozyme PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.004/8/2024INZYInozyme PharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$15.003/14/2024SPRBSpruce BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$8.00 ➝ $3.003/14/2024SPRBSpruce BiosciencesLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVDLAvadel Pharmaceuticals$27.96M51.28N/AN/A$0.98 per share16.15FIXXHomology Medicines$1.16M0.00N/AN/A$1.26 per share0.00INZYInozyme PharmaN/AN/AN/AN/A$2.27 per shareN/ASIGASIGA Technologies$139.92M3.94$0.74 per share10.52$2.77 per share2.80SPRBSpruce Biosciences$10.09M3.42N/AN/A$1.88 per share0.45Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVDLAvadel Pharmaceuticals-$160.28M-$2.04N/A18.62N/AN/A-198.06%-84.51%8/14/2024 (Estimated)FIXXHomology Medicines-$112.96M-$1.96N/AN/AN/A-4,779.31%-102.52%-74.91%N/AINZYInozyme Pharma-$71.17M-$1.39N/AN/AN/AN/A-55.86%-40.71%8/13/2024 (Estimated)SIGASIGA Technologies$68.07M$0.958.166.51N/A48.65%44.84%36.64%8/13/2024 (Estimated)SPRBSpruce Biosciences-$47.92M-$1.25N/AN/AN/A-474.96%-52.31%-39.77%5/20/2024 (Estimated)Latest FIXX, SPRB, AVDL, INZY, and SIGA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2024Q1 2024AVDLAvadel Pharmaceuticals-$0.25-$0.30-$0.05-$0.30$25.89 million$27.18 million 3/13/2024Q4 2023SPRBSpruce Biosciences-$0.41-$0.23+$0.18-$0.23$1.65 million$2.89 million3/12/2024Q4 2023INZYInozyme Pharma-$0.31-$0.35-$0.04-$0.35N/AN/A3/12/2024Q4 2023SIGASIGA TechnologiesN/A$1.01+$1.01$1.01N/A$116.48 million3/4/2024Q4 2023AVDLAvadel Pharmaceuticals-$0.28-$0.32-$0.04-$0.29$17.41 million$19.45 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/AFIXXHomology MedicinesN/AN/AN/AN/AN/AINZYInozyme PharmaN/AN/AN/AN/AN/ASIGASIGA TechnologiesN/AN/AN/AN/AN/ASPRBSpruce BiosciencesN/AN/AN/AN/AN/ALatest FIXX, SPRB, AVDL, INZY, and SIGA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/12/2024SIGASIGA Technologies$0.603/25/20243/26/20244/11/2024(Data available from 1/1/2013 forward)DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVDLAvadel PharmaceuticalsN/A3.643.36FIXXHomology MedicinesN/A7.257.25INZYInozyme Pharma0.3213.3613.36SIGASIGA TechnologiesN/A4.423.23SPRBSpruce Biosciences0.024.184.18OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVDLAvadel Pharmaceuticals69.19%FIXXHomology Medicines31.32%INZYInozyme Pharma88.30%SIGASIGA Technologies55.40%SPRBSpruce Biosciences91.71%Insider OwnershipCompanyInsider OwnershipAVDLAvadel Pharmaceuticals4.00%FIXXHomology Medicines16.10%INZYInozyme Pharma11.88%SIGASIGA Technologies2.17%SPRBSpruce Biosciences9.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAVDLAvadel Pharmaceuticals15490.58 million86.95 millionOptionableFIXXHomology Medicines758.13 million48.77 millionOptionableINZYInozyme Pharma5961.86 million54.51 millionOptionableSIGASIGA Technologies4571.12 million69.58 millionOptionableSPRBSpruce Biosciences2941.15 million37.41 millionOptionableFIXX, SPRB, AVDL, INZY, and SIGA HeadlinesSourceHeadlineINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - April 30 at 9:30 PMSpruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meetingfinance.yahoo.com - April 30 at 7:33 PMSpruce Biosciences Inc (SPRB)investing.com - April 26 at 10:14 PMSpruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meetingbusinesswire.com - April 22 at 4:05 PMIMPORTANT INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - April 19 at 4:00 AMINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - April 5 at 7:00 AMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRBprnewswire.com - April 4 at 7:15 PMONGOING SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - April 4 at 7:00 AMONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - April 3 at 3:30 AMONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - April 1 at 6:00 AMINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - March 30 at 6:20 PMIMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - March 29 at 5:00 AMINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - March 28 at 3:30 AMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRBprnewswire.com - March 27 at 5:36 PMSpruce Biosciences (SPRB) Upgraded to Buy: Here's What You Should Knowzacks.com - March 27 at 1:01 PMINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - March 27 at 3:30 AMINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - March 26 at 3:30 AMONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - March 25 at 4:30 AMINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - March 24 at 7:00 AMRevenue Downgrade: Here's What Analysts Forecast For Spruce Biosciences, Inc. (NASDAQ:SPRB)finance.yahoo.com - March 23 at 10:38 AMINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - March 23 at 7:00 AMINVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - March 22 at 7:00 AMHoldings A/S Novo Sells 359,979 Shares of Spruce Biosciences, Inc. (NASDAQ:SPRB) Stockinsidertrades.com - March 22 at 6:24 AMSpruce Biosciences (SPRB) Falls 86% in a Month: Here's Whyzacks.com - March 21 at 11:21 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAvadel PharmaceuticalsNASDAQ:AVDLAvadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Homology MedicinesNASDAQ:FIXXHomology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.Inozyme PharmaNASDAQ:INZYInozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.SIGA TechnologiesNASDAQ:SIGASIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.Spruce BiosciencesNASDAQ:SPRBSpruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.